Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.33 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088079 | 1.00 | KDM4C (0.42) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL31059829 | 1.00 | KDM4C (0.42) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL31059631 | 1.00 | KDM4C (0.42) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL12782211 | 0.84 | KDM4C (0.41) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL23343770 | 0.83 | KDM4C (0.39) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL908395 | 0.83 | KDM4C (0.41) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL4016788 | 0.79 | LMNA (0.44) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL4016781 | 0.79 | LMNA (0.44) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL4016785 | 0.79 | LMNA (0.44) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 | |
| SCHEMBL19228426 | 0.79 | KDM4C (0.36) | KDM4CALDH1A1MAPTL3MBTL1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024178335-A2 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | KDM4C 2393/4885ALDH1A1 3824/4885MAPT 1924/4885 |
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK20, CDK3 | KDM4C 3614/4885ALDH1A1 4325/4885MAPT 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.